Chief Executive Officer: Anil Panwar
Delivering quality services
Fortis Clinical Research Ltd (FCRL) is a leading full service Indian CRO operational since 2005, providing clinical research services to the pharmaceutical, biotechnology and device companies across the globe. It comprehensive drug-development services focused on expert quality and cost effective solutions for end-to-end management of clinical trials. Its state-of-the-art facility is spread over 19,000 sq. ft. and four floors of the Sunflag Hospital and Research Center in Faridabad (near Delhi).
Within a short duration of eight years, FCRL has been able to garner major projects. During FY 2012-13, the company recorded revenues of `344.40 crore as compared to `287 crore in the FY 2011-12. It was one of the four CROs joining the Maximax Pharmaceutical Research, which launched a global CRO alliance (CRO Development Group). The infrastructure consists of a 78-bed ward, two-bed ICU, phlebotomy stations, pharmacy, bioanalytical labs with LCMS and HPLC machines.
The company boasts of a rich bank of healthy volunteers drawn from the local community in Faridabad and Delhi/NCR and is currently conducting bioequivalence studies with generic products in healthy volunteers and clinical studies (phase 1 to IV) in healthy volunteers and patients at investigator sites as its main service offering. It has also conducted number of BE studies in young, healthy female volunteers, post-menopausal female volunteers.
According to Mr Anil Panwar, CEO, FCRL there are many areas where it is ahead of its competitors. "Our central laboratory was India's first to get ISO 15189:2007 NABL and CAP accreditation. We have experience of over 550 clinical trials for over 35 therapeutic segments. We have a 24-hour dedicated sample archiving facility, dedicated clinical research service department and real time web-based online reporting systems. We extend the services to about eight million patients annually. The FCRL team excels in end-to-end management across all the clinical and pharmacovigilance studies," concluded
Company: Fortis Clinical research Limited
Business: Clinical research/drug development services
Revenue: 2013 `344.40 crore